GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vepdegrestrant   Click here for help

GtoPdb Ligand ID: 11511

Synonyms: ARV-471 | ARV471 | compound 341 [WO2018102725A1] | PF-07850327 | PF07850327 | Veppanu®
Approved drug
vepdegrestrant is an approved drug
Compound class: Synthetic organic
Comment: Vepdegrestrant (ARV471) is a bifunctional compound that is estrogen receptor (ER) degrader (PROTAC) [1]. It uses a cereblon-based binder to direct ER protein degradation. ARV471 is orally bioavailable, and was proposed for potential to treat breast cancer. Vepdegrestrant was the first PROTAC to gain clinical approval (from the US FDA, May 2026).

vepdegrestrant is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 96.43
Molecular weight 723.38
XLogP 7.16
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=C1CCC(C(=O)N1)N1Cc2c(C1=O)ccc(c2)N1CCN(CC1)CC1CCN(CC1)c1ccc(cc1)[C@H]1[C@H](CCc2c1ccc(c2)O)c1ccccc1
Isomeric SMILES O=C1CCC(C(=O)N1)N1Cc2c(C1=O)ccc(c2)N1CCN(CC1)CC1CCN(CC1)c1ccc(cc1)[C@H]1[C@H](CCc2c1ccc(c2)O)c1ccccc1
InChI InChI=1S/C45H49N5O4/c51-37-12-15-39-33(27-37)8-13-38(31-4-2-1-3-5-31)43(39)32-6-9-35(10-7-32)48-20-18-30(19-21-48)28-47-22-24-49(25-23-47)36-11-14-40-34(26-36)29-50(45(40)54)41-16-17-42(52)46-44(41)53/h1-7,9-12,14-15,26-27,30,38,41,43,51H,8,13,16-25,28-29H2,(H,46,52,53)/t38-,41?,43+/m1/s1
InChI Key TZZDVPMABRWKIZ-MFTLXVFQSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
The first study to evaluate vepdegestrant (ARV471) for ER+/HER2- locally advanced or metastatic breast cancer evaluated it as a monotherapy compared to in combination with the CDK4/6 kinase inhibitor palbociclib. The compound was advanced to phase 3. The FDA approved vepdegestrant in May 2026, to treat ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04072952 A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer Phase 1/Phase 2 Interventional Arvinas Inc
NCT05909397 A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer Phase 3 Interventional Pfizer
NCT05654623 A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer Phase 3 Interventional Pfizer The VERITAC-2 study: vepdegestrant failed improve progression-free survival (PFS) compared to the estrogen receptor (ER) antagonist in this study. Some benefit may be discernable in a subset of patients with ER1 (ERα) mutations, but this remains to be verified. 2